Author: Bloom, Kristie; Maepa, Mohube Betty; Ely, Abdullah; Arbuthnot, Patrick
Title: Gene Therapy for Chronic HBV—Can We Eliminate cccDNA? Document date: 2018_4_12
ID: 0dr9eans_4
Snippet: Several novel anti-HBV therapeutics are in preclinical development or early clinical trial (reviewed by [15, 16] ). Most candidate drugs are small molecule drugs designed to impede various stages of HBV replication. Affordable next-generation NAs, which inhibit the viral polymerase with reduced toxicity and higher barriers to HBV resistance are currently the preferred first-line of therapy. Other direct-acting antivirals include HBV core protein .....
Document: Several novel anti-HBV therapeutics are in preclinical development or early clinical trial (reviewed by [15, 16] ). Most candidate drugs are small molecule drugs designed to impede various stages of HBV replication. Affordable next-generation NAs, which inhibit the viral polymerase with reduced toxicity and higher barriers to HBV resistance are currently the preferred first-line of therapy. Other direct-acting antivirals include HBV core protein allosteric modulators [17, 18] , HBV surface antigen (HBsAg) release inhibitors [19, 20] and nucleic acid polymers which also inhibit viral entry [21] . With the discovery that the sodium taurocholate co-transporting polypeptide (NTCP) facilitates HBV entry into hepatocytes [22] , peptide inhibitors such as Myrcludex-B (NCT02881008 and NCT02888106) are also being developed for therapeutic application [23] . Another popular host-related strategy has been to recondition the immune system using interferons, cytokines, and peptides as immune modulators which are discussed in more detail below (Section 3.3).
Search related documents:
Co phrase search for related documents- allosteric modulator and core protein: 1
- allosteric modulator and viral entry: 1
- candidate drug and clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- candidate drug and core protein: 1
- candidate drug and HBsAg antigen surface: 1
- candidate drug and HBV replication: 1
- candidate drug and high barrier: 1, 2
- candidate drug and immune system: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- candidate drug and molecule drug: 1, 2, 3, 4, 5, 6
- candidate drug and peptide inhibitor: 1, 2, 3, 4, 5, 6, 7
- candidate drug and preclinical development: 1, 2, 3, 4
- candidate drug and reduce toxicity: 1
- candidate drug and viral entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- candidate drug and viral polymerase: 1, 2, 3, 4, 5
- clinical trial and co transporting polypeptide: 1
- clinical trial and core protein: 1
- clinical trial and direct act: 1
- clinical trial and early clinical trial: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44
- clinical trial and high barrier: 1, 2
Co phrase search for related documents, hyperlinks ordered by date